Vivanza Biosciences Q2 FY27 Results: Net Profit ₹0.1 Cr, Down 83.3% YoY
Vivanza Biosciences Ltd reported revenue from operations of ₹11.4 Cr (-79.4% YoY) and net profit of ₹0.1 Cr (-83.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹0.1 Cr · -83.3% YoY
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Vivanza Biosciences Ltd reported revenue from operations of ₹11.4 Cr (-79.4% YoY) and net profit of ₹0.1 Cr (-83.3% YoY) for Q2 FY27.
Vivanza Biosciences has scheduled a Board meeting on November 3, 2026 to approve unaudited Q2 and H1 FY27 financial results. No other material agenda items are listed.
Vivanza Biosciences Ltd has filed a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026.
Vivanza Biosciences has convened its 44th AGM on September 11, 2026 via VC/OAVM. Nine agenda items cover financial statements, director appointments, and borrowing limit approvals.
Vivanza Biosciences Limited has scheduled its 44th Annual General Meeting for September 11, 2026. The company also released its full Annual Report for the financial year 2025-26.
Vivanza Biosciences approved its annual reports, the convening of the 44th AGM, and various procedural resolutions including borrowing limits and related party transactions for upcoming periods.
Vivanza Biosciences has scheduled a board meeting for August 17, 2026, to discuss the AGM, financial reports, and various corporate authorizations under the Companies Act.